Prevalence of osteoporosis in Korean prostate cancer patients who is receiving LHRH agonist and/or anti-androgen agent
Study identifier:NIS-OKR-CAS-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Prevalence of osteoporosis in Korean prostate cancer patients who is receiving LHRH agonist and/or anti-androgen agent
Medical condition
prostate cancer
Phase
-
Healthy volunteers
No
Study drug
-
Sex
Male
Actual Enrollment
829
Study type
Observational
Age
N/A
Date
Study Start Date: 01 Nov 2009
Primary Completion Date: 01 Mar 2010
Study Completion Date: 01 Mar 2010
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jun 2010 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Joon Woo Bahn
AstraZeneca Korea
